Orphazyme A/S

Equities

ORPHA

DK0062502894

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:46:28 2024-06-04 EDT			5-day change	1st Jan Change
999.7 ^DKK	0.00%		-1.49%	-24.83%

03-27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

Orphazyme Appoints Christophe Bourdon as Chief Executive Officer, Effective April 1, 2021

March 25, 2021 at 08:00 am

Orphazyme announced the appointment of Christophe Bourdon as its new Chief Executive Officer, effective as of April 1, 2021. He joins from Amgen Inc., where he has held the role of Senior Vice President, General Manager for the U.S. Oncology Business.

Latest news about Orphazyme A/S

Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
FDA Extends Review of Zevra's Arimoclomol by Three Months	03-04	DJ
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	02-20	CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA	12-27	DJ
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	23-09-12	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	23-05-30	CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO	23-05-30	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-05-30	CI
Orphazyme A/S Announces Board Changes	23-05-17	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-04-25	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Orphazyme A/S(CPSE:ORPHA) added to OMX Nordic Small Cap Index	23-01-03	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-26	CI
Orphazyme A/S Revises Earnings Guidance for the Year 2022	22-09-25	CI
Orphazyme A/S Announces Board Appointment	22-06-29	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-07	CI
Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022	22-06-07	CI
Orphazyme Closes $18 Million Sale Of Assets, Business Operations Under Restructuring Plan	22-06-01	MT
KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.	22-05-30	CI
Orphazyme A/S Announces Executive Changes	22-05-23	CI
Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index	22-05-20	CI
KemPharm Agrees to Buy Orphazyme for $12.8 Million	22-05-16	MT
KemPharm Denmark A/S agreed to acquire substantially all assets and business activities of Orphazyme A/S for $18 million.	22-05-14	CI
Orphazyme's American Depositary Shares Delisted From Nasdaq	22-04-01	MT

Chart Orphazyme A/S

Duration

Period

More charts

Company Profile

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Companyâs candidate, arimoclomol, stimulates the production of the cellsâ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cellsâ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORPHAZYME A/S	-24.83%	5.15M
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	121B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.82B
ARGENX SE	+1.69%	22.48B
GENMAB A/S	-10.09%	18.32B
WUXI APPTEC CO., LTD.	-40.52%	16.33B
BEIGENE, LTD.	-14.00%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	14.08B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.74B

Bio Therapeutic Drugs